{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:14:43Z","timestamp":1788250483064,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Fujian Provincial Natural Science Foundation of China","award":["2026J001559"],"award-info":[{"award-number":["2026J001559"]}]},{"name":"the Joint Funds for the Innovation of Science and Technology of Fujian Province","award":["2025Y9289"],"award-info":[{"award-number":["2025Y9289"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11060-026-05706-0","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T02:36:15Z","timestamp":1784687775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The persistent benefit of chemotherapy in elderly lung adenocarcinoma patients with brain metastases in the immunotherapy era"],"prefix":"10.1007","volume":"179","author":[{"given":"Yingjiao","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenjie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhuo","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"5706_CR1","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. (2021). Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249","DOI":"10.3322\/caac.21660"},{"key":"5706_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS (2021) Lung cancer. Lancet 398:535\u2013554","journal-title":"Lancet"},{"key":"5706_CR3","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","volume":"19","author":"DN Cagney","year":"2017","unstructured":"Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ et al (2017) Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol 19:1511\u20131521","journal-title":"Neuro Oncol"},{"key":"5706_CR4","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE et al (2015) Nivolumab versus Docetaxel in Advanced Nonsquamous Non\u2013Small-Cell Lung Cancer. N Engl J Med 373:1627\u20131639","journal-title":"N Engl J Med"},{"key":"5706_CR5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/JCO.20.01605","volume":"39","author":"H Borghaei","year":"2021","unstructured":"Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J et al (2021) Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non\u2013Small-Cell Lung Cancer. J Clin Oncol 39:723\u2013733","journal-title":"J Clin Oncol"},{"key":"5706_CR6","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3747\/co.20.1481","volume":"20","author":"A Ali","year":"2013","unstructured":"Ali A, Goffin JR, Arnold A, Ellis PM (2013) Survival of Patients with Non-Small-Cell Lung Cancer after a Diagnosis of Brain Metastases. Curr Oncol 20:300\u2013306","journal-title":"Curr Oncol"},{"key":"5706_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41568-019-0220-y","volume":"20","author":"A Boire","year":"2019","unstructured":"Boire A, Brastianos PK, Garzia L, Valiente M (2019) Brain metastasis. Nat Rev Cancer 20:4\u201311","journal-title":"Nat Rev Cancer"},{"key":"5706_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1634\/theoncologist.6-suppl_1-4","volume":"6","author":"C Gridelli","year":"2001","unstructured":"Gridelli C (2001) The ELVIS Trial: A Phase III Study of Single-Agent Vinorelbine as First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer. Oncologist 6:4\u20137","journal-title":"Oncologist"},{"key":"5706_CR9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.lungcan.2003.09.012","volume":"43","author":"A Kanard","year":"2004","unstructured":"Kanard A, Jatoi A, Castillo R, Geyer S, Schulz TK, Fitch TR et al (2004) Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity. Lung Cancer 43:345\u2013353","journal-title":"Lung Cancer"},{"key":"5706_CR10","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0140-6736(11)60780-0","volume":"378","author":"E Quoix","year":"2011","unstructured":"Quoix E, Zalcman G, Oster J-P, Westeel V, Pichon E, Lavol\u00e9 A et al (2011) Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 378:1079\u20131088","journal-title":"Lancet"},{"key":"5706_CR11","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00408-012-9399-3","volume":"190","author":"W-X Qi","year":"2012","unstructured":"Qi W-X, Tang L-n, He A-n, Shen Z, Lin F, Yao Y (2012) Doublet Versus Single Cytotoxic Agent as First-Line Treatment for Elderly Patients with Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Lung 190:477\u2013485","journal-title":"Lung"},{"key":"5706_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/BF00686291","volume":"30","author":"MG Donelli","year":"1992","unstructured":"Donelli MG, Zucchetti M, D\u2019Incalci M (1992) Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 30:251\u2013260","journal-title":"Cancer Chemother Pharmacol"},{"key":"5706_CR13","doi-asserted-by":"crossref","unstructured":"Lassman AB, Rossi MR, Razier JR, Abrey LE, Lieberman FS, Grefe CN, et al. (2005). Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01\u201303 and 00\u201301. Clin Cancer Res 11:7841\u20137850","DOI":"10.1158\/1078-0432.CCR-05-0421"},{"key":"5706_CR14","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1093\/annonc\/mdr003","volume":"22","author":"F Barlesi","year":"2011","unstructured":"Barlesi F, Gervais R, Lena H, Hureaux J, Berard H, Paillotin D et al (2011) Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07\u2009\u2013\u200901). Ann Oncol 22:2466\u20132470","journal-title":"Ann Oncol"},{"key":"5706_CR15","first-page":"491","volume":"14","author":"O Bailon","year":"2012","unstructured":"Bailon O, Chouahnia K, Augier A, Bouillet T, Billot S, Coman I et al (2012) Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma. Neurooncology 14:491\u2013495","journal-title":"Neurooncology"},{"key":"5706_CR16","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F et al (2018) Pembrolizumab plus Chemotherapy in Metastatic Non\u2013Small-Cell Lung Cancer. N Engl J Med 378:2078\u20132092","journal-title":"N Engl J Med"},{"key":"5706_CR17","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, G\u00fcm\u00fc\u015f M, Mazi\u00e8res J et al (2018) Pembrolizumab plus Chemotherapy for Squamous Non\u2013Small-Cell Lung Cancer. N Engl J Med 379:2040\u20132051","journal-title":"N Engl J Med"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05706-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05706-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05706-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:27:21Z","timestamp":1788247641000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05706-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5706"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05706-0","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"14 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Since data released by the SEER database was publicly available, ethics approval and informed patient consent was not required for this study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"7"}}